Mid-term analysis of DESTINY-Lung01 in Phase II trials showed meaningful clinical activity in the treatment of HER2 mutant non-small cell lung cancer patients, with 61.9% of patients receiving tumor remission

The results of the ongoing Phase II clinical trial destinY-Lung01 show that AstraZeneca and The Third Of AstraZeneca have achieved clinical lying in patients with one or more systems treated with one or more systems for disease progression in patients with non-reprecision and/or metastatic non-squamous lung cancer (NSCLC)lung cancer is the leading cause of cancer deaths in both men and women, accounting for about one-fifth of all cancer deaths worldwide80-85% of lung cancer is non-small cell lung cancerHER2 mutations account for about 2% to 4% of non-small cell lung cancer, and there is no approved drug for the treatment of HER2 mutation non-small cell lung cancerThe main endpoint of this study is the confirmed objective remission rate (ORR), based on the evaluation of the independent evaluation committee, the ORR was 61.9% for patients treated with DS-8201 single drug (6.4 mg/kg), 90.5% for disease control (DCR) and 14.0 months for median progression(PFS)Median mitigation duration (DoR) and total lifetime (OS) have not been reached by the time the test data is cut off"Despite significant advances in the treatment of lung cancer over the past decade, there are still some patients who continue to develop tumors even after new targeted drugs or immunotherapy," said Egbert FSmit, M.D., a professor of chest oncology at the Dutch Cancer Institute, lead researcher of the Phase II clinical trial destinyUnderstanding other driving gene states, such as HER2, is critical to improving treatment choices in these patientsIn the DESTINY-Lung01 trial, the results seen are encouraging"The results observed in patients treating metastatic non-small cell lung cancer with the HER2 mutation in DS-8201 are very exciting and demonstrate the potential to become a new treatment option for patients with such prognosis extremely poor," said Jos? Baselga, Global Executive Vice President and Head of Oncology Research and Development atAstraZenecaMore importantly, DS-8201 has the potential to treat other types of her-positive tumors that meet the high clinical needsAntoine Yver, Executive Vice President and Global Head of Cancer Research and Development at the, said: "The treatment of HER2-positive breast and stomach cancer by DS-8201 has established a good position in the past, but there is no approval for anti-HER2 targeted treatment for lung cancerThese results confirm that HER2 mutations are targeted for lung cancer treatment, and That DS-8201 has the potential to alter the prognosis of such patients "
the results of the study, patients received previously moderate two-line systemic therapy (1-6), most of which received platinum-containing chemotherapy (90.5%) and anti-PD-1 or PD-L1 treatment (54.8%) The median treatment time was 7.76 months (0.7-14.3) and the median follow-up time was 8.0 months (1.4-14.2) As of November 25, 2019, 45.2% of HER2 mutation metastatic non-small cell lung cancer patients are still receiving DS-8201 treatment DS-8201's overall safety and tolerance in DESTINY-Lung01 were consistent with previous stage I lung cancer trials and other DS-8201 trials 4 The most common treatment-related adverse events of level 3 or above were neutrope% reduction (26.2%) and anemia (16.7%) An independent jury assessed that five cases (11.9%) were diagnosed with the treatment of intersothelional pulmonary disease (ILD) and pneumonia All ILDs and pneumonia are level 2 1 patient with grade 1 ILD, which is still being evaluated The results of the DESTINY-Lung01 trial were announced at the 2020 American Clinical Oncology Annual Meeting (ASCO) from May 29 to 31, 2020 Some of the key clinical research data presented at the conference will demonstrate AstraZeneca's leadership in early and late lung cancer, further strengthening the company's strategy for drug development based on biomarkers DS-8201 was recently awarded a breakthrough therapy by the FDA for the treatment of HER2m- mutation-metastatic non-small cell lung cancer statement: The use of drugs in these studies has not been approved in China, AstraZeneca does not recommend any unapproved drug use References
1 Bray F, et al Global cancer statistics 2018: GLOBOCANs of the city of and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018; 68:394-424.6.
2 JD Campbell, et al patterns of somatic genome sin lung adenocarcinomas and squamous cell carcinomas Nat Genet 2016 Jun; 48 (6):607-16.
3 Li BT, et al HER2 ascal and HER2 mutation are distinct molecular targets in lung cancers J Thorac Oncol 2016 Mar; 11 (3): 414-419.
4 Tsurutani, J et al Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Advanced Solid Solid Solid Tumors Cancer Discov 2020; 10(5) DOI: 10.1158/2159-8290.CD-19-1014.